<?xml version="1.0" encoding="UTF-8"?>
<ref id="B48-viruses-12-00276">
 <label>48.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Monnet</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Jorieux</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Souyris</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Zaki</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Jacquet</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Fournier</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Crozet</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>de Romeuf</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Bouayadi</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Urbain</surname>
    <given-names>R.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody</article-title>
  <source>MAbs</source>
  <year>2014</year>
  <volume>6</volume>
  <fpage>422</fpage>
  <lpage>436</lpage>
  <pub-id pub-id-type="doi">10.4161/mabs.27854</pub-id>
  <pub-id pub-id-type="pmid">24492301</pub-id>
 </element-citation>
</ref>
